Overview

A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2020-11-28
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Japanese participants with type 2 diabetes. Side effects and tolerability will be documented. Blood samples will be taken to compare how the body handles the drug and how it affects blood sugar levels. The study will last almost five months for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin, Globin Zinc
Insulin, Long-Acting